Abstract
Studies of cancer based solely on health insurance claims data typically lack information on cancer clinical characteristics that are strong predictors of treatment and prognosis. Our objective was to evaluate routinely collected cancer clinical data for adjustment of confounding using an example evaluation of mortality associated with aromatase inhibitors and tamoxifen. This cohort study identified women with breast cancer from 2008 through 2010 using health insurance claims data linked to clinical information on stage at diagnosis, current clinical status, histology, and other clinical markers. Estimated mortality rates (MRs) and 95% confidence intervals (CI) were compared between users of aromatase inhibitors or tamoxifen, adjusted for claims-identified covariates and additionally for the clinical variables using propensity scores and proportional hazards regression models. The overall (n = 7974) estimated MR was 69/1000 person-years (95%CI = 62-76 person-years), 308/1000 person-years (95% CI = 273-345 person-years) for women with metastasis, and 12/1000 person-years (95%CI = 8-16 person-years) for women without active cancer. Propensity score matching of aromatase inhibitor users (n = 777) with tamoxifen users (n = 535) rem...Continue Reading
References
Dec 15, 1996·American Journal of Epidemiology·L BlaisS Suissa
Jan 9, 2001·Journal of Clinical Epidemiology·D A McKenzieL E McCamant
Aug 17, 2002·Methods : a Companion to Methods in Enzymology·Joanna S FowlerYu-Shin Ding
Oct 31, 2003·American Journal of Epidemiology·Wayne A Ray
Dec 17, 2003·The American Journal of Cardiology·John D SeegerFrank M Sacks
Dec 23, 2004·Epidemiology·Sebastian SchneeweissDaniel H Solomon
Jul 1, 2005·American Journal of Epidemiology·Til StürmerRobert J Glynn
Feb 1, 2006·Pharmacoepidemiology and Drug Safety·Sebastian Schneeweiss
Dec 7, 2006·Epidemiology·Timothy L Lash
Mar 31, 2007·American Journal of Epidemiology·Til StürmerRobert J Glynn
Oct 25, 2007·Medical Care·Til StürmerSebastian Schneeweiss
Jan 25, 2008·Pharmacoepidemiology and Drug Safety·P Mona EngAlexander M Walker
Jun 3, 2009·Epidemiology·Sebastian SchneeweissM Alan Brookhart
Nov 23, 2010·The Lancet Oncology·Jack CuzickUNKNOWN ATAC/LATTE investigators
Feb 16, 2011·Diabetes, Obesity & Metabolism·D D DoreJ D Seeger
Aug 17, 2011·Pharmacoepidemiology and Drug Safety
Jan 1, 2007·American Journal of Epidemiology·Til StürmerRobert J Glynn
Citations
May 11, 2012·Pharmacoepidemiology and Drug Safety·Sebastian SchneeweissScott R Smith
Oct 13, 2014·Computer Methods and Programs in Biomedicine·K RickettsA Gibson
Apr 16, 2016·Medicine·Hervé Tchala Vignon ZomahounLine Guénette
Sep 29, 2017·Journal of Neuro-oncology·Charlotte KellyMatt Williams